This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (currently amended): Substituted pyrazoline compounds of ~~general~~ formula I,



I

wherein

R^1 represents hydrogen or a linear or branched C_{1-4}-alkyl group,

R^2, R^3 and R^4 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^8, SH, SR^8, SOR^8, SO_2R^8, NH_2, NHR^8, NR^8R^9, -(C=O)-NH_2, -(C=O)-NHR^8 or -(C=O)-NR^8R^9 whereby R^8 and R^9 for each substituent independently represent linear or branched C_{1-6} alkyl,

R^5 and R^6 independently of each other represent a linear or branched C_{1-6} alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^{10}, SH, SR^{10}, SOR^{10}, NH_2, NHR^{10}, $NR^{10}R^{11}$, -(C=O)-NH_2, -(C=O)-NHR^{10} ~~and~~ or -(C=O)-$NR^{10}R^{11}$, whereby R^{10} and optionally R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl,

R^7 represents hydrogen, a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^{10}, SH, SR^{10}, SOR^{10}, NH_2,

NHR^{10}, $NR^{10}R^{11}$ -(C=O)-NH_2, -(C=O)NHR^{10} ~~and~~ or -(C=O)-$NR^{10}R^{11}$, whereby R^{10} and optionally R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl,

with the proviso that

if R^1 and R^7 are H and R^5 and R^6 both represent Cl in the 3- and 4-position of the phenyl ring neither of R^2, R^3 and R^4 may represent F in the 4-position of the phenyl ring if the other two of R^2, R^3 and R^4 both represent H,

optionally in a form of one ~~of the~~ its stereoisomers~~, preferably enantiomers or diastereomers,~~ or a racemate or in a form of a mixture of at least two ~~of the~~ its stereoisomers, ~~preferably enantiomers and/or diastereomers,~~ in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

2. (original): Compounds according to claim 1, characterized in that at least one of R^2, R^3 or R^4 represents hydrogen, while at least one of R^2, R^3 or R^4 is different from hydrogen.

3. (currently amended): Compounds according to ~~any one of claims~~ claim 1 ~~or 2~~, characterized in that R^7 represents hydrogen.

4. (currently amended): Compounds according to ~~any one of claims~~ claim 1 ~~to 3~~, characterized in that R^2, R^3 and R^4 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a halogen atom, or CF_3~~, preferably R^2, R^3 and R^4 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF_3~~.

5. (currently amended): Compounds according to ~~any one of claims~~ claim 1 ~~to~~ 4, characterized in that R^5 and R^6 independently of each other represent a linear or branched C_{1-6}-alkyl group, a halogen atom, or CF_3~~, preferably R^5 and R^6 independently of each other represent methyl, ethyl, F, Cl, Br and CF_3~~.

6. (currently amended): Compounds according to ~~any one of claims~~ claim 1 ~~to 5~~, characterized in that R^2 represents a chlorine atom in the 4-positlon of the phenyl ring, while R^3 and R^4 represent hydrogen.

7. (currently amended): Compounds according to ~~any one of claims~~ claim 1 ~~to 6~~, characterized in that R^5 and R^6 each represent ~~a~~ chlorine atoms in the 2- and 4-position of the phenyl ring, while R^7 represents hydrogen.

8. (currently amended): Compounds according to ~~any one of claims~~ claim 1 ~~to 7~~, characterized in that R^1 represents hydrogen, methyl or ethyl, ~~preferably hydrogen~~.

9. (currently amended): Compounds of ~~general~~ formula II according to ~~any one of claims~~ claim 1 ~~to 8~~



II

wherein

R^1 represents hydrogen or a linear or branched C_{1-4}-alkyl group,

R^{12} or R^{13} independently of each other represent a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, SH, NH_2, hydrogen, methyl, ethyl, F, Cl, Br ~~and~~ or CF_3,

R^{14} or R^{15} independently of each other represent a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, SH, NH_2, methyl, ethyl, F, Cl, Br ~~and~~ or CF_3,

optionally in a form of one of ~~the~~ its stereoisomers~~, preferably enantiomers or diastereomers,~~ or a racemate or in a form of a mixture of at least two of ~~the~~ its stereoisomers, ~~preferably enantiomers and/or diastereomers,~~ in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

10. (currently amended): Compounds according to claim 9 characterized in that R^{12} and R^{13} independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a halogen atom, or CF_3~~, preferably R^{12} and R^{13} independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF_3~~.

11. (currently amended): Compounds according to ~~any one of claims~~ claim 9 ~~or 10~~, characterized in that R^{14} and R^{15} independently of each other represent a linear or branched C_{1-6}-alkyl group, a halogen atom, or CF_3~~, preferably R^{14} and R^{15} independently of each other represent methyl, ethyl, F, Cl, Br and CF_3~~.

12. (currently amended): Compounds according to ~~any one of claims~~ claim 9 ~~to 11~~, characterized in that R^{13} represents Cl and R^{12} represents hydrogen.

13. (currently amended): Compounds according to ~~any one of claims~~ claim 9 ~~to 12~~, characterized in that R^{14} and R^{15} each represent Cl.

14. (currently amended): Compounds according to ~~any one of claims~~ claim 9 ~~to 13~~, characterized in that R^1 represents hydrogen, methyl or ethyl~~, preferably hydrogen~~.

15. (currently amended): A compound ~~Compounds~~ according to ~~one or more of claims~~ claim 1 ~~to 14 selected from the group consisting of~~ which is:

5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxylic acid,

optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.

16. (currently amended): Combination of compounds comprising at least one substituted pyrazoline compound of ~~general~~ formula I



I

wherein

R^1 represents hydrogen or a linear or branched C_{1-4}-alkyl group,

R^2, R^3 and R^4 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^8, SH, SR^8, SOR^8, SO_2R^8, NH_2, NHR_8, NR^8R^9, -(C=O)-NH_2, -(C=O)-NHR^8 or -(C=O)-NR^8R^9 whereby R^8 and R^9 for each substituent independently represent linear or branched C_{1-6}-alkyl,

R^5, R^6 and R^7 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^{10}, SH, SR^{10}, SOR^{10}, NH_2, NHR^{10}, $NR^{10}R^{11}$, -(C=O)-NH_2, -(C=O)-NHR^{10} ~~and~~ or -(C=O)-$NR^{10}R^{11}$, whereby R^{10} and optionally R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl;

optionally in a form of one ~~of the~~ its stereoisomers~~, preferably enantiomers or diastereomers,~~ or a racemate or in a form of a mixture of at least two of ~~the~~ its stereoisomers, ~~preferably enantiomers and/or diastereomers,~~ in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

and at least one substituted pyrazoline compound of general formula X



X

wherein

R^{16} represents an optionally at least mono-substituted phenyl group,

R^{17} represents an optionally at least mono-substituted phenyl group,

R^{18} represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an -$NR^{19}R^{20}$-moiety,

R^{19} and R^{20}, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system ~~and/or~~ or bonded via a linear or branched alkylene group, an -SO_2-R^{21}-moiety, or an -$NR^{22}R^{23}$-moiety, with the proviso that R^{19} and R^{20} do not identically represent hydrogen,

R^{21} represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system ~~and/or~~ or bonded via a linear or branched alkylene group,

R^{22} and R^{23}, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system ~~and/or~~ or bonded via a linear or branched alkylene group,

optionally in a form of one of ~~the~~ its stereoisomers, ~~preferably enantiomers or diastereomers,~~ or a racemate or in a form of a mixture of at least two of ~~the~~ its stereoisomers, ~~preferably enantiomers and/or diastereomers,~~ in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

Claims 17-39 (canceled)

40. (currently amended): Process for the manufacture of substituted pyrazoline compounds of ~~general~~ formula I or II, wherein R^1 is hydrogen, according to ~~one or more of claims~~ claim 1 ~~to 15~~, characterized in that at least one benzaldehyde compound of ~~general~~ formula III



(III)

wherein R^2, R^3 and R^4 have the meaning according to ~~one or more of claims 1-8~~ claim 1, is reacted with a pyruvate compound of ~~general~~ formula (IV)



(IV),

wherein G represents an OR group with R being a branched or unbranched C_{1-6} alkyl radical or G represents an O^-K group with K being a cation, to yield a compound of ~~general~~ formula (V)



(V)

which is optionally isolated ~~and/or~~ or optionally purified, and which is reacted with an optionally substituted phenyl hydrazine of ~~general~~ formula (VI)



(VI)

or a corresponding salt thereof, wherein R^5, R^6 and R^7 have the meaning according to ~~one or more of claims 1-8~~ claim 1, under inert atmosphere, to yield a compound of ~~general~~ formula (VII)



(VII)

wherein R^2, R^3, R^4, R^5, R^6 and R^7 have the meaning as given above, which is optionally isolated ~~and/or~~ or optionally purified, and optionally esterified to an alkyl-ester if in the substituted pyrazoline compound of ~~general~~ formula I according to ~~one or more of claims~~ claim ~~1 to 15~~ R^1 is a linear or branched C_{1-4}-alkyl group.

41. (currently amended): Medicament comprising at least one substituted pyrazoline compound of ~~general~~ formula I or II according to ~~one or more of claims~~ claim ~~1 to 15~~, and optionally one or more pharmaceutically acceptable excipients.

42. (currently amended): Medicament comprising at least one substituted pyrazoline compound of general formula I



I

wherein

R^1 represents hydrogen or a linear or branched C_{1-4}-alkyl group,

R^2, R^3 and R^4 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^8, SH, SR^8, SOR^8, SO_2R^8, NH_2, NHR^8, NR^8R^9, -(C=O)-NH_2, -(C=O)-NHR^8 or -(C=O)-NR^8R^9 whereby R^8 and R^9 for each substituent independently represent linear or branched C_{1-6} alkyl,

R^5, R^6 and R^7 independently of each other represent hydrogen, a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R^{10}, SH, SR^{10}, SOR^{10}, NH_2, NHR^{10}, $NR^{10}R^{11}$, -(C=O)-NH_2, -(C=O)-NHR^{10} ~~and~~ or -(C=O)-$NR^{10}R^{11}$, whereby R^{10} and optionally R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl;

optionally in a form of one ~~of the~~ its stereoisomers~~, preferably enantiomers or diastereomers,~~ or a racemate or in a form of a mixture of at least two of ~~the~~ its stereoisomers, ~~preferably enantiomers~~

~~and/or diastereomers,~~ in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof;

and optionally one or more pharmaceutically acceptable excipients.

Claims 43-64 (canceled)

65. (currently amended): A method ~~Use of at least one substituted pyrazoline compound according to one or more of claims 1-15 or at least one combination of compounds according to one or more of claims 16 to 39 and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament~~ for the regulation of triglyceride levels in the blood plasma or ~~and~~ for the prophylaxis ~~and/or~~ or treatment of disorders ~~of disorders~~ of the central nervous system, ~~especially stroke, of disorders of the cardiovascular system and~~ or of food intake disorders, ~~especially bulimia, anorexia, cachexia, obesity, type II diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis~~, the method comprising administering one or more substituted pyrazoline compounds of claim 1 and optionally one or more pharmaceutically acceptable excipients.

Claims 66-86 (canceled)